Download - Stoke Clinical Trial
-
8/6/2019 Stoke Clinical Trial
1/70
linical trials inlinical trials introke an overviewtroke an overviewr Melvin George
-
8/6/2019 Stoke Clinical Trial
2/70
IntroductionIntroduction
v Stroke remains a leading cause of death.and disability worldwide
v Recombinant tissue plasminogen activator( ) -rtPA in acute ischemic stroke has
improved the clinical outcome ofpatients who present early after onset
.of symptoms
-
8/6/2019 Stoke Clinical Trial
3/70
linical trials inlinical trials instroketroke Acute ischemic stroke trials
Acute hemorragic stroke trials
Stroke Prevention trials
Stroke rehabilitation trials
-
8/6/2019 Stoke Clinical Trial
4/70
Acute ischemic stroke trialsAcute ischemic stroke trials
-
8/6/2019 Stoke Clinical Trial
5/70
A randomized controlled trialof antiplatelet therapy in
-combination with rt PA :thrombolysis in ischemic stroke
rationale and design of the
-ARTIS Trial
-
8/6/2019 Stoke Clinical Trial
6/70
Hypotheses:Hypotheses:
Immeditate addition of antiplateletImmeditate addition of antiplatelettherapy to rt-PA in acute ischemictherapy to rt-PA in acute ischemic
stroke improves outcome by enhancingstroke improves outcome by enhancingclot lysis and preventing re-occlusionclot lysis and preventing re-occlusionafter initial recanalisation.after initial recanalisation.
-
8/6/2019 Stoke Clinical Trial
7/70
Primary objectivePrimary objective
To investigate whether theaddition of aspirin to standard
-rt PA thrombolysis reduces poor
outcome in acute ischemic.stroke
-
8/6/2019 Stoke Clinical Trial
8/70
v o o r o u t c o m e i s d e f i n e d a s d e a t ho o r o u t c o m e i s d e f i n e d a s d e a t hr d e p e n d e n c y a s s e s s e d b y t h er d e p e n d e n c y a s s e s s e d b y t h e( ,o d i f i e d R a n k i n S c a l e m R S s c o r e( ,o d i f i e d R a n k i n S c a l e m R S s c o r e- ) - .6 a t 3 m o n t h s f o l l o w u p) - .6 a t 3 m o n t h s f o l l o w u p
-
8/6/2019 Stoke Clinical Trial
9/70
-
8/6/2019 Stoke Clinical Trial
10/70
ankin scoreankin scorev Most widely used clinical outcome
.measure for stroke clinical trialsvv It was originally introduced in 1957 by
Rankin
-
8/6/2019 Stoke Clinical Trial
11/70
Modified Rankin ScoreModified Rankin Score(mRS)(mRS)
corecore escriptionescription0 o symptoms at allo symptoms at all1 ;o significant disability despite symptoms able;o significant disability despite symptoms ableo carry out all usual duties and activitieso carry out all usual duties and activities2 ;light disability unable to carry out all;light disability unable to carry out all,revious activities but able to look after own,revious activities but able to look after ownffairs without assistanceffairs without assistance3 ; ,oderate disability requiring some help but able; ,oderate disability requiring some help but ableo walk without assistanceo walk without assistance4 ;oderately severe disability unable to walk;oderately severe disability unable to walkithout assistance and unable to attend to ownithout assistance and unable to attend to ownodily needs without assistanceodily needs without assistance5 ; ,evere disability bedridden incontinent and; ,evere disability bedridden incontinent andequiring constant nursing care and attentionequiring constant nursing care and attention6 Deadead
-
8/6/2019 Stoke Clinical Trial
12/70
Inclusion criteriaInclusion criteria
. -ge 18 80 years. atients with acute ischemic stroke3.Exclusion crit eriaExclusion crit eria
1. nown antiplatelet therapy in the previous(days in
ase of uncertainty the patient may be);ncluded
. nown thrombocytopenia
. -nown contra indications to acetylsalicylic;cid treatment
. nown anticogualant therapy in the previous 5
-
8/6/2019 Stoke Clinical Trial
13/70
-
8/6/2019 Stoke Clinical Trial
14/70
Recommendations forRecommendations forrtPArtPA
q Diagnosis of ischemic stroke causingmeasurable neurological deficit
q Neurological signs should not beclearing spontaneously
q Neurological signs should not be minorand isolated
q Symptoms not suggestive of intracerebralhaemorrhage
-
8/6/2019 Stoke Clinical Trial
15/70
Recommendations forRecommendations forrtPArtPA
q
-
8/6/2019 Stoke Clinical Trial
16/70
Recommendations forRecommendations forrtPArtPA
q No evidence of active bleedingq Not taking anticoagulantq ,If on heparin aPTT must be in normal
range
q > /Blood glucose 50 mg dlq >Platelet count 100 000 mm3
-
8/6/2019 Stoke Clinical Trial
17/70
Recommendations forRecommendations forrtPArtPA
q CT does not show multilobar infarction(hypodensity greater than one third of
)cerebral hemisphere
q No seizure with residual neurologic deficitq ( >Blood pressure not elevated systolic 185
> )mm Hg and diastolic 110 mm Hgq The patient or family members understand
the potential risks and benefits from.treatmentq
-
8/6/2019 Stoke Clinical Trial
18/70
RandomizationRandomization
andomisation procedure will beandomisation procedure will be- ,omputer and web based using,omputer and web based using.ermuted blocks.ermuted blocks andomisation will be stratifiedandomisation will be stratifiedyy
,entre,entre ( , > ),ge 60 years 60 years( , > ),ge 60 years 60 years genderender ime between symptom onset and timeime between symptom onset and time- (< , -f rt PA bolus 2 hours 2 3- (< , -f rt PA bolus 2 hours 2 3, > ).ours 3 hours> ).ours 3 hours
-
8/6/2019 Stoke Clinical Trial
19/70
Aspirin will be administered within 1.5hours after the rt-PA bolus.
Patient and treating physician are notblinded for treatment allocation.
Why Aspirin intravenously?
-
8/6/2019 Stoke Clinical Trial
20/70
Treatment of acute ischemicTreatment of acute ischemicstrokestroke
. / ( )nfuse 0 9 mg kg maximum dose 90 mg over 60 minutes%ith 10 of the dose given as a bolus over 1.inute
dmit the patient to an intensive care or stroke.nit for monitoring
erform neurological assessments every 15 minutesuring the infusion and every 30 minutes
,hereafter for the next 6 hours then hourly.ntil 24 hours after treatment ,f the patient develops severe headache acute
, , ,ypertension nausea or vomiting discontinue the( )nfusion if rtPA is being administered and
-
8/6/2019 Stoke Clinical Trial
21/70
-
8/6/2019 Stoke Clinical Trial
22/70
Blood pressure should not belowered with medication prior to
- .rt PA treatment
-
8/6/2019 Stoke Clinical Trial
23/70
Rescue therapyRescue therapy
- , >If during rt PA administration SBP 180> ,mmHg or DBP 105 mmHg administer 10
- .mg labetalol iv in 1 2 minutes
-Repeat every 10 20 minutes until bloodpressure is below 180 mmHg systolic or
.below 105 mmHg diastolic
-
8/6/2019 Stoke Clinical Trial
24/70
Rescue therapyRescue therapy
150 mg labetalol is the maximum dose in.24 hours
During this treatment blood pressure
.should be measured every 15 minutes If the blood pressure does not respond
, . -to labetalol iv nitroprusside 0 5 10/ / ,g kg minute should be added with
.continuous blood pressure monitoring
-
8/6/2019 Stoke Clinical Trial
25/70
All medication used before the stroke,may be continued except
.anticoagulants Simvastatin dipyridamole
-
8/6/2019 Stoke Clinical Trial
26/70
OUTCOME MEASURESOUTCOME MEASURES
The primary endpoint is poor functionalhealth at 3 months defined as
( - ).dependency or death mRS 3 6
difi d ki
-
8/6/2019 Stoke Clinical Trial
27/70
Modified Rankin ScoreModified Rankin Score(mRS)(mRS)
corecore escriptionescription0 o symptoms at allo symptoms at all1 ;o significant disability despite symptoms able;o significant disability despite symptoms ableo carry out all usual duties and activitieso carry out all usual duties and activities2 ;light disability unable to carry out all;light disability unable to carry out all,revious activities but able to look after own,revious activities but able to look after ownffairs without assistanceffairs without assistance3 ; ,oderate disability requiring some help but able; ,oderate disability requiring some help but ableo walk without assistanceo walk without assistance4 ;oderately severe disability unable to walk;oderately severe disability unable to walkithout assistance and unable to attend to ownithout assistance and unable to attend to ownodily needs without assistanceodily needs without assistance5 ; ,evere disability bedridden incontinent and; ,evere disability bedridden incontinent andequiring constant nursing care and attentionequiring constant nursing care and attention6 Deadead
-
8/6/2019 Stoke Clinical Trial
28/70
v rimary outcome will be assessed by a blindesearch nurse from the clinical trial
,ffice of the coordinating centre whoill score the mRS by telephone using a
.tructured interview
v -o increase the inter observer reliabilityhe number of research nurses will be
.imited to a maximum of three
S dS d t
-
8/6/2019 Stoke Clinical Trial
29/70
Secondary outcomeSecondary outcomemeasuresmeasures
v Complications within 48 hours after randomisationincluding the occurrence of SICH and serious
.systemic bleeding
v SICH is defined as -CT documented haemorrhage Clinical deterioration leading to 4 or more
points increase on the National Institute of( )Health Stroke Scale NIHSS as compared to
.the best score on the NIHSS since admission
-
8/6/2019 Stoke Clinical Trial
30/70
What is the NIHSS?What is the NIHSS?
-
8/6/2019 Stoke Clinical Trial
31/70
-
8/6/2019 Stoke Clinical Trial
32/70
-
8/6/2019 Stoke Clinical Trial
33/70
-
8/6/2019 Stoke Clinical Trial
34/70
-
8/6/2019 Stoke Clinical Trial
35/70
-
8/6/2019 Stoke Clinical Trial
36/70
-
8/6/2019 Stoke Clinical Trial
37/70
-
8/6/2019 Stoke Clinical Trial
38/70
-
8/6/2019 Stoke Clinical Trial
39/70
-
8/6/2019 Stoke Clinical Trial
40/70
-
8/6/2019 Stoke Clinical Trial
41/70
-
8/6/2019 Stoke Clinical Trial
42/70
-
8/6/2019 Stoke Clinical Trial
43/70
-
8/6/2019 Stoke Clinical Trial
44/70
-
8/6/2019 Stoke Clinical Trial
45/70
-
8/6/2019 Stoke Clinical Trial
46/70
-
8/6/2019 Stoke Clinical Trial
47/70
-
8/6/2019 Stoke Clinical Trial
48/70
-
8/6/2019 Stoke Clinical Trial
49/70
Secondary outcomeSecondary outcomemeasuresmeasures
neurological symptoms quantified by the NIHSS 7 -10 days after randomisation or at discharge if the
patient is discharged within 7 days;
survival at 3 months;
disability at 3 months assessed by the AMC Linear
Disablility Scale
functional health at 3 months non-dichotomized(ordinal mRS);
causes of poor outcome
-
8/6/2019 Stoke Clinical Trial
50/70
Data collectionData collection
Age,
sex,
ethnicity,
medical history,
pre-stroke medication,
pre-stroke mRS,
blood pressure,
Glasgow Coma Scale (GCS),
National Institutes of Health Stroke Scale (NIHSS),
time of symptom onset,
-
8/6/2019 Stoke Clinical Trial
51/70
v -Baseline CT scans will be collected from
participating centres and assessed
blindly centrally at the coordinatingcentre by an independent blinded
- .neuro radiologist
v
-
8/6/2019 Stoke Clinical Trial
52/70
- ,At follow up neurological deficits are- .assessed by the NIHSS at 7 10 days
-
8/6/2019 Stoke Clinical Trial
53/70
SAESAE
,Clinical deterioration defined as a 4 or,more points increase on the NIHSS
-will be followed by CT scan and
( )registration as serious adverseevents including possible cause by.each participating site
-
8/6/2019 Stoke Clinical Trial
54/70
All adverse event reported by the subjects
or observed by the treating physicians
.will be recorded
( ),In case of serious adverse events SAE the
principal investigator will be notified
.by email or telephone within 24 hours
The principal investigator subsequently
reports SAE to the Data Safety Monitoring
( ).Board DSMB
-
8/6/2019 Stoke Clinical Trial
55/70
DSMBDSMB
safety surveillances
recommend the Steering Committee toterminate the trial if clear evidence
.of harm
unblinded
interim analysis on the
primary outcome to assess the strengthof the efficacy data
-
8/6/2019 Stoke Clinical Trial
56/70
DecisionsDecisions
:Possible decisionsContinue with trial as planned
:Stop safety problem
:Stop efficacy established: (Stop new knowledge usually from other trials
)suggesting risks: .Stop futile Trial unlikely to show a result
Modify trial design
-
8/6/2019 Stoke Clinical Trial
57/70
Haemorragic stroke trialHaemorragic stroke trial
To evaluate the safety and
effectiveness of lowering blood
pressure using nicardipine in personswith acute hypertension associated
.with intracerebral hemorrhage
-
8/6/2019 Stoke Clinical Trial
58/70
Inclusion criteriaInclusion criteria
.Age older than 18 years Onset of new neurological signs of a
stroke within 12 hours of the time to
evaluation AND initiation of treatment.with intravenous nicardipine Clinical signs consistent with the
,diagnosis of stroke including
, ,impairment of language motor function, / , ,cognition and or gaze vision or.neglect
-
8/6/2019 Stoke Clinical Trial
59/70
Inclusion criteriaInclusion criteria
he total GCS score is greater than 8 at the time of.nrollment
T scan demonstrates intraparenchymal hematoma with.anual hematoma volume measurement less than 60 cc
,CH is supratentorial and is located in lobar basal,anglionic or thalamic based on the initial CT scan.ppearance
dmission systolic blood pressure greater than 170 mmg on two repeat measurements at least 5 minutes.part
.vidence of chronic hypertension ubject is not considered a surgical candidate by the
-
8/6/2019 Stoke Clinical Trial
60/70
AVERTAVERTA Very Early RehabilitationA Very Early Rehabilitation
TrialTrial
-
8/6/2019 Stoke Clinical Trial
61/70
To determine if very early mobilization( )VEM of stroke patients in addition to
standard care compared to standard
( )care SC alone is more effective in, ,lowering mortality disability andseverity of complications at 3 months
and at improving quality of life at 12
.months
-
8/6/2019 Stoke Clinical Trial
62/70
:Primary Outcome
.Modified Rankin Score at 3 months
Secondary outcome
.barthel pdf
ARISTOTLEARISTOTLE
http://smb//tmp/svpf5.tmp/barthel.pdfhttp://smb//tmp/svpf5.tmp/barthel.pdfhttp://smb//tmp/svpf5.tmp/barthel.pdf -
8/6/2019 Stoke Clinical Trial
63/70
ARISTOTLEARISTOTLE
APIXABAN FOR THEPREVENTION OF STROKE INSUBJECTS WITH ATRIAL
FIBRILLATION
-
8/6/2019 Stoke Clinical Trial
64/70
,s a p i x a b a n a n i n v e s t i g a t i o n a l,s a p i x a b a n a n i n v e s t i g a t i o n a ln t i c o a g u l a n t i s a s e f f e c t i v e a sn t i c o a g u l a n t i s a s e f f e c t i v e a s( )t a n d a r d t h e r a p y w a r f a r i n i n( )t a n d a r d t h e r a p y w a r f a r i n i nr e v e n t i n g s t r o k e a n d s y s t e m i cr e v e n t i n g s t r o k e a n d s y s t e m i cm b o l i s m i n s u b j e c t s w i t h a t r i a lm b o l i s m i n s u b j e c t s w i t h a t r i a li b r i l l a t i o n a n d r i s k f a c t o r s f o ri b r i l l a t i o n a n d r i s k f a c t o r s f o rt r o k e ?t r o k e ?
-
8/6/2019 Stoke Clinical Trial
65/70
Inclusion CriteriaInclusion Criteria
Males and females 18 yrs with AF one or more of the following risk
:factors for stroke
,Age 75 ,previous stroke ,TIA or Systemic Embolism symptomatic congestive heart failure or left ventricular dysfunction with LVEF
%,40 diabetes mellitus or hypertension requiring pharmacological
.treatment
-
8/6/2019 Stoke Clinical Trial
66/70
:r i m a r y O u t c o m e :r i m a r y O u t c o m e onfirmed stroke or systemiconfirmed stroke or systemic. (mbolism time to first(mbolism time to first)ccurrence)ccurrence
:e c o n d a r y O u t c o m e :e c o n d a r y O u t c o m e ,onfirmed ischemic stroke,onfirmed ischemic stroke,emorrhagic stroke systemic,emorrhagic stroke systemic, . (mbolism all cause death time to. (mbolism all cause death time to)irst occurrence)irst occurrence
-
8/6/2019 Stoke Clinical Trial
67/70
-eath primary outcome in some.troke trials Problems
voiding dependency is moremportant to stroke patients than.ying eath is inefficient statistically- nly a minority of patients inost trials
-
8/6/2019 Stoke Clinical Trial
68/70
-
8/6/2019 Stoke Clinical Trial
69/70
ConclusionConclusion
Numerous trials in acute strokehave been performed
Few advances made
Sound knowledge of methodology
of trials can supplement thescientific progress in basicresearch.
-
8/6/2019 Stoke Clinical Trial
70/70